Efficacy and safety of cyclin‐dependent kinase 4/6 inhibitor in patients with advanced breast cancer: A real‐world experience

Tzu‐Rong Peng,Jia‐Hui Chen,Ta‐Wei Wu
DOI: https://doi.org/10.1111/1759-7714.15090
IF: 3.223
2023-09-06
Thoracic Cancer
Abstract:A total of 85 patients were included in the analysis, with a mean age of 66.8 years. After a median follow‐up of 16.1 months, the median PFS was 28.4 months (95% CI: 22.5–33.6) and the median OS could not yet be estimated. The most common adverse events (AE) were fatigue (50.8%), anorexia (45.9%), and leukopenia (44.7%). In multivariable analysis, treatment with CDK4/6i with any grade AE or response to treatment effect (CR/PR) was an independent predictor for longer PFS (hazard ratio [HR] = 0.27, 95% CI: 0.11–0.68; HR = 0.21, 95% CI: 0.06–0.67; p
oncology,respiratory system
What problem does this paper attempt to address?